Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.

摘要: Background Effective new therapies are needed for rheumatoid arthritis. Current target the products of activated macrophages; however, T cells also have an important role in A fusion protein — cytotoxic T-lymphocyte–associated antigen 4–IgG1 (CTLA4Ig) is first a class drugs known as costimulation blockers being evaluated treatment CTLA4Ig binds to CD80 and CD86 on antigen-presenting cells, blocking engagement CD28 preventing T-cell activation. preliminary study showed that may be effective Methods We randomly assigned patients with active arthritis despite methotrexate therapy receive 2 mg per kilogram body weight (105 patients), 10 (115 or placebo (119 patients) six months. All received during study. The clinical response was assessed at mo...